A Comparative Efficacy and Safety Study of Long-Acting Risperidone Injection and Risperidone Oral Tablets Among Hospitalized Patients: 12-Week Randomized, Single-Blind Study

• DOI: 10.1055/s-2006-946703
• Publication Date: 2009-01-29T10:14:51Z
• Authors: Y. Bai; T. Chen; B. Wu; C. Hung; W. Lin; T. Hu; C.-Y. Lin; P. Chou
• Keywords: Adult; Male; Inpatients; Adolescent; Administration, Oral; Middle Aged; Risperidone; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Injections, Intravenous; Quality of Life; Schizophrenia; Humans; Female; Schizophrenic Psychology; Single-Blind Method; Aged; Antipsychotic Agents

Objective: The superiority of risperidone long-acting injection (RLAI) over oral typical and atypical antipsychotics demonstrated in previous studies may be related to the improved drug compliance. aim 12-week randomized, single-blind study was test whether RLAI remained among hospitalized patients that compliance could optimally controlled. Methods: Fifty stable schizophrenic patients, who had maintained on for more than 3 months, were randomized group. Finally 49 (98 %) completed study, no dose change risperidone, or noted all patients. Results: group showed significantly increased positive score Positive Negative Syndrome Scale (PANSS) (0.72 ± 3.52 vs. –1.24 3.81, p = 0.022), but without significance difference PANSS total, negative general psychopathology scores. also a Udvalg Kliniske Undersogelser (UKU) (p 0.037), social life domains Short-From Health Survey (SF-36) 0.011), reduced prolactin level 0.001). Conclusion: results indicated with optimal controlling benefit efficacy advantages side-effect profiles, ratings, levels.